Palvella Therapeutics (PVLA) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Palvella Therapeutics (NASDAQ:PVLA) will report Q1 2026 results before the market opens on May 7, 2026, with analysts forecasting EPS of ($0.90) for the quarter.
• Shares recently traded around $128.32, with a 12‑month low/high of $20.20/$151.18, a market cap of $1.84 billion and a negative PE of -34.59; the 50‑ and 200‑day moving averages are $124.68 and $101.01.
• Insider activity includes COO Kathleen Goin selling ~4,302 shares and Director George M. Jenkins buying 4,000 shares, while Wall Street consensus rates the stock a “Moderate Buy” with an average target of $198.07.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) is projected to announce its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.90) per share for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by ($0.13). On average, analysts expect Palvella Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Palvella Therapeutics Price Performance

Shares of PVLA opened at $128.32 on Friday. Palvella Therapeutics has a 12 month low of $20.20 and a 12 month high of $151.18. The stock's 50-day moving average is $124.68 and its two-hundred day moving average is $101.01. The stock has a market cap of $1.84 billion, a PE ratio of -34.59 and a beta of -0.21.

Insider Activity at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the firm's stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director George M. Jenkins acquired 4,000 shares of the company's stock in a transaction on Friday, February 27th. The shares were acquired at an average price of $125.00 per share, for a total transaction of $500,000.00. Following the completion of the acquisition, the director directly owned 187,171 shares in the company, valued at $23,396,375. The trade was a 2.18% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 20.50% of the stock is currently owned by company insiders.

Institutional Trading of Palvella Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in PVLA. Group One Trading LLC lifted its position in shares of Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company's stock worth $35,000 after purchasing an additional 200 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Palvella Therapeutics by 11.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company's stock worth $429,000 after purchasing an additional 433 shares in the last quarter. Bank of America Corp DE increased its holdings in Palvella Therapeutics by 12.3% in the third quarter. Bank of America Corp DE now owns 4,689 shares of the company's stock valued at $294,000 after buying an additional 515 shares during the last quarter. Deutsche Bank AG increased its holdings in Palvella Therapeutics by 8.7% in the fourth quarter. Deutsche Bank AG now owns 6,594 shares of the company's stock valued at $690,000 after buying an additional 528 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Palvella Therapeutics during the third quarter valued at approximately $36,000. Institutional investors own 40.11% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. BTIG Research raised their target price on Palvella Therapeutics from $192.00 to $215.00 and gave the company a "buy" rating in a report on Wednesday, February 25th. Truist Financial set a $210.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. Mizuho lifted their price objective on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the company an "outperform" rating in a research note on Wednesday, February 25th. TD Cowen reissued a "buy" rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. Finally, Chardan Capital upped their target price on shares of Palvella Therapeutics from $210.00 to $240.00 and gave the company a "buy" rating in a research note on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Palvella Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $198.07.

About Palvella Therapeutics

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.